Efficacy and Safety of ALT-801 in the Treatment of Obesity
Primary Purpose
Obesity/Overweight
Status
Active
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
ALT-801
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Obesity/Overweight
Eligibility Criteria
Inclusion Criteria:
- Written informed consent signed prior to entry into the study
- Male or female age 18 to 75 years, inclusive
- Body mass index (BMI) ≥ 30 kg/m2 or BMI ≥ 27 kg/m2 combined with at least one obesity-related comorbidity
- At least one unsuccessful weight loss attempt per investigator judgement
- Agreement to comply with the study-required life-style intervention and treatment during the full duration of the study
- Female subjects of childbearing potential who are not pregnant or breastfeeding, do not plan to become pregnant during the study, and agree to use effective birth control
Exclusion Criteria:
- Weight gain or loss > 5% in the 3 months prior to randomization or >10% in the 6 months prior to screening
Diabetes and related conditions:
- History or clinical evidence of diabetes mellitus of any type, including Type 1, Type 2, or mature onset diabetes of the young (MODY)
- HbA1c > 6.5%, fasting glucose ≥ 126 mg/dL (6.9 mmol/L), and/or random glucose of ≥ 200 mg/dL (11.0mmol/L) at screening
Obesity and related conditions:
- Obesity induced by known genetic causes or endocrine disorders (eg, Cushing Syndrome, inadequately treated hypothyroidism, defined as thyroid-stimulating hormone [TSH] > 6 mIU/L)
- History of bariatric surgery or other surgical treatment for obesity (eg, gastric banding, gastric bypass), or planned surgery or surgical treatment during the study. Liposuction and/or abdominoplasty performed >1 year before screening is allowed. Endoscopically placed intragastric balloons will be allowed if removed > 1 year before screening.
Gastrointestinal conditions:
- History of acute or chronic pancreatitis within 1 year (365 days) before screening
- History of or acute significant gastrointestinal (GI) disorder (eg, peptic ulcers, severe gastroesophageal reflux disease [GERD],
- History of GI surgery, including cholecystectomy and antrectomy. Surgery for appendicitis and small bowel resection >20cm is acceptable.
- History of inflammatory bowel disease, celiac disease or any medical condition or surgery that could affect gastric emptying, stool frequency or stool consistency. (Irritable bowel syndrome is permitted provided that bowel frequency and consistency are normal off treatment.)
Mental health conditions:
- Untreated depressive disorder, defined as a Patient Health Questionaire-9 (PHQ-9) score of ≥ 15 at screening
- Suicide ideation, defined as type 4 or 5 on the Columbia-Suicide Severity Rating Scale(C-SSRS) at screening, lifelong history of a suicide attempt, or suicidal behavior within 30 days before screening
- Other severe psychiatric disorder (eg, schizophrenia, bipolar disorder)
Sites / Locations
- Altimmune CTM
- Altimmune CTM
- Altimmune CTM
- National Research Institute
- Altimmune CTM
- Altimmune CTM
- Altimmune CTM
- Altimmune CTM
- Altimmune CTM
- Altimmune CTM
- Altimmune CTM
- Altimmune CTM
- Altimmune CTM
- Altimmune CTM
- Altimmune CTM
- Midwest Institute for Clinical Research
- Altimmune CTM
- Altimmune CTM
- Altimmune CTM
- Altimmune CTM
- Altimmune CTM
- Altimmune CTM
- Altimmune CTM
- Cornell University, Joan and Sanford Weill Medical College
- Altimmune CTM
- Altimmune CTM
- Altimmune CTM
- Altimmune CTM
- Altimmune CTM
- Altimmune CTM
- Altimmune CTM
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Experimental
Experimental
Placebo Comparator
Arm Label
ALT-801 Dose Level 1
ALT-801 Dose Level 2
ALT-801 Dose Level 3
Placebo
Arm Description
Outcomes
Primary Outcome Measures
Relative change from baseline in body weight percentage
Secondary Outcome Measures
Percent proportion of subjects with weight loss of greater than or equal to 5%, 10%, and 15%
Change from baseline in lipids
The Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs)
Changes from baseline in Fasting Glucose
Changes from baseline in Hemoglobin A1c
Changes from baseline in Homeostatic Marker Assessment for Insulin Resistance (HOMA-IR)
Changes from baseline in: a) Systolic blood pressure, b) Diastolic blood pressure
Change from baseline in proportion of patients using antihypertensive medications
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05295875
Brief Title
Efficacy and Safety of ALT-801 in the Treatment of Obesity
Official Title
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled and Parallel Group 48-Week Study to Evaluate the Efficacy and Safety of ALT-801 in the Treatment of Obesity (MOMENTUM Trial)
Study Type
Interventional
2. Study Status
Record Verification Date
September 2022
Overall Recruitment Status
Active, not recruiting
Study Start Date
March 31, 2022 (Actual)
Primary Completion Date
August 2023 (Anticipated)
Study Completion Date
September 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Altimmune, Inc.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This study will evaluate the efficacy and safety of ALT-801 once-weekly versus placebo as an adjunct to a reduced-calorie diet and increased physical activity in patients with obesity/overweight.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity/Overweight
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
320 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
ALT-801 Dose Level 1
Arm Type
Experimental
Arm Title
ALT-801 Dose Level 2
Arm Type
Experimental
Arm Title
ALT-801 Dose Level 3
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
ALT-801
Intervention Description
Injected subcutaneously (SC)
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Injected subcutaneously (SC)
Primary Outcome Measure Information:
Title
Relative change from baseline in body weight percentage
Time Frame
Baseline to Week 48
Secondary Outcome Measure Information:
Title
Percent proportion of subjects with weight loss of greater than or equal to 5%, 10%, and 15%
Time Frame
Baseline to Week 48
Title
Change from baseline in lipids
Time Frame
Baseline to Week 48
Title
The Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs)
Time Frame
Baseline to Week 48
Title
Changes from baseline in Fasting Glucose
Time Frame
Baseline to Week 48
Title
Changes from baseline in Hemoglobin A1c
Time Frame
Baseline to Week 48
Title
Changes from baseline in Homeostatic Marker Assessment for Insulin Resistance (HOMA-IR)
Time Frame
Baseline to Week 48
Title
Changes from baseline in: a) Systolic blood pressure, b) Diastolic blood pressure
Time Frame
Baseline to Week 48
Title
Change from baseline in proportion of patients using antihypertensive medications
Time Frame
Baseline to Week 48
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Written informed consent signed prior to entry into the study
Male or female age 18 to 75 years, inclusive
Body mass index (BMI) ≥ 30 kg/m2 or BMI ≥ 27 kg/m2 combined with at least one obesity-related comorbidity
At least one unsuccessful weight loss attempt per investigator judgement
Agreement to comply with the study-required life-style intervention and treatment during the full duration of the study
Female subjects of childbearing potential who are not pregnant or breastfeeding, do not plan to become pregnant during the study, and agree to use effective birth control
Exclusion Criteria:
Weight gain or loss > 5% in the 3 months prior to randomization or >10% in the 6 months prior to screening
Diabetes and related conditions:
History or clinical evidence of diabetes mellitus of any type, including Type 1, Type 2, or mature onset diabetes of the young (MODY)
HbA1c > 6.5%, fasting glucose ≥ 126 mg/dL (6.9 mmol/L), and/or random glucose of ≥ 200 mg/dL (11.0mmol/L) at screening
Obesity and related conditions:
Obesity induced by known genetic causes or endocrine disorders (eg, Cushing Syndrome, inadequately treated hypothyroidism, defined as thyroid-stimulating hormone [TSH] > 6 mIU/L)
History of bariatric surgery or other surgical treatment for obesity (eg, gastric banding, gastric bypass), or planned surgery or surgical treatment during the study. Liposuction and/or abdominoplasty performed >1 year before screening is allowed. Endoscopically placed intragastric balloons will be allowed if removed > 1 year before screening.
Gastrointestinal conditions:
History of acute or chronic pancreatitis within 1 year (365 days) before screening
History of or acute significant gastrointestinal (GI) disorder (eg, peptic ulcers, severe gastroesophageal reflux disease [GERD],
History of GI surgery, including cholecystectomy and antrectomy. Surgery for appendicitis and small bowel resection >20cm is acceptable.
History of inflammatory bowel disease, celiac disease or any medical condition or surgery that could affect gastric emptying, stool frequency or stool consistency. (Irritable bowel syndrome is permitted provided that bowel frequency and consistency are normal off treatment.)
Mental health conditions:
Untreated depressive disorder, defined as a Patient Health Questionaire-9 (PHQ-9) score of ≥ 15 at screening
Suicide ideation, defined as type 4 or 5 on the Columbia-Suicide Severity Rating Scale(C-SSRS) at screening, lifelong history of a suicide attempt, or suicidal behavior within 30 days before screening
Other severe psychiatric disorder (eg, schizophrenia, bipolar disorder)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sarah K Browne, MD
Organizational Affiliation
Altimmune, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Altimmune CTM
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35020
Country
United States
Facility Name
Altimmune CTM
City
Mesa
State/Province
Arizona
ZIP/Postal Code
85201
Country
United States
Facility Name
Altimmune CTM
City
Los Angeles
State/Province
California
ZIP/Postal Code
90001
Country
United States
Facility Name
National Research Institute
City
Los Angeles
State/Province
California
ZIP/Postal Code
90057
Country
United States
Facility Name
Altimmune CTM
City
Montclair
State/Province
California
ZIP/Postal Code
91763
Country
United States
Facility Name
Altimmune CTM
City
Santa Barbara
State/Province
California
ZIP/Postal Code
93101
Country
United States
Facility Name
Altimmune CTM
City
Boca Raton
State/Province
Florida
ZIP/Postal Code
33427
Country
United States
Facility Name
Altimmune CTM
City
Clearwater
State/Province
Florida
ZIP/Postal Code
33755
Country
United States
Facility Name
Altimmune CTM
City
Fort Myers
State/Province
Florida
ZIP/Postal Code
33900
Country
United States
Facility Name
Altimmune CTM
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32201
Country
United States
Facility Name
Altimmune CTM
City
Port Orange
State/Province
Florida
ZIP/Postal Code
32123
Country
United States
Facility Name
Altimmune CTM
City
Sunrise
State/Province
Florida
ZIP/Postal Code
33319
Country
United States
Facility Name
Altimmune CTM
City
Savannah
State/Province
Georgia
ZIP/Postal Code
31411
Country
United States
Facility Name
Altimmune CTM
City
Evanston
State/Province
Illinois
ZIP/Postal Code
60201
Country
United States
Facility Name
Altimmune CTM
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46201
Country
United States
Facility Name
Midwest Institute for Clinical Research
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46260
Country
United States
Facility Name
Altimmune CTM
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40202
Country
United States
Facility Name
Altimmune CTM
City
Baton Rouge
State/Province
Louisiana
ZIP/Postal Code
70801
Country
United States
Facility Name
Altimmune CTM
City
New Orleans
State/Province
Louisiana
ZIP/Postal Code
70119
Country
United States
Facility Name
Altimmune CTM
City
Kansas City
State/Province
Missouri
ZIP/Postal Code
64101
Country
United States
Facility Name
Altimmune CTM
City
Butte
State/Province
Montana
ZIP/Postal Code
59701
Country
United States
Facility Name
Altimmune CTM
City
Berlin
State/Province
New Jersey
ZIP/Postal Code
08009
Country
United States
Facility Name
Altimmune CTM
City
New York
State/Province
New York
ZIP/Postal Code
10001
Country
United States
Facility Name
Cornell University, Joan and Sanford Weill Medical College
City
New York
State/Province
New York
ZIP/Postal Code
10065
Country
United States
Facility Name
Altimmune CTM
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45201
Country
United States
Facility Name
Altimmune CTM
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19092
Country
United States
Facility Name
Altimmune CTM
City
Knoxville
State/Province
Tennessee
ZIP/Postal Code
37901
Country
United States
Facility Name
Altimmune CTM
City
Austin
State/Province
Texas
ZIP/Postal Code
78701
Country
United States
Facility Name
Altimmune CTM
City
Bellaire
State/Province
Texas
ZIP/Postal Code
77401
Country
United States
Facility Name
Altimmune CTM
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78201
Country
United States
Facility Name
Altimmune CTM
City
Saint George
State/Province
Utah
ZIP/Postal Code
84770
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Efficacy and Safety of ALT-801 in the Treatment of Obesity
We'll reach out to this number within 24 hrs